Heart Failure Remission: Can You Stop Your Medication?

What happened when recovered patients stopped heart failure medication?

The TRED-HF pilot trial enrolled people with previous dilated cardiomyopathy whose symptoms, heart pumping function and other measurements had improved substantially. Among 25 participants assigned to supervised medication withdrawal, 11 relapsed within six months; none of the 26 assigned to continue treatment relapsed during that period. The findings appeared in The Lancet in 2019. [TRED-HF trial](https://pmc.ncbi.nlm.nih.gov/articles/PMC6319251/)

Relapse included deterioration detected through imaging or a blood marker of cardiac stress, as well as clinical heart failure. It therefore did not necessarily mean hospitalization or an immediately obvious return of symptoms. The small trial studied withdrawal of a treatment regimen, so it could not establish which individual medicine was indispensable. Its findings also cannot automatically be applied to every cause of heart failure.

Does relapse remain a concern years after heart function improves?

The longer-term report, published online in 2024 and in a 2025 issue of the European Journal of Heart Failure, found that 65% of participants had met relapse criteria since enrollment. This total includes events during the original trial and subsequent follow-up; it is not the proportion who newly relapsed after the trial ended. [Long-term TRED-HF follow-up](https://pmc.ncbi.nlm.nih.gov/articles/PMC11798629/)

After the trial, treatment decisions returned to patients' clinical teams, and medication intensity varied. The extended study therefore lacked a continuing randomized comparison capable of isolating the long-term effect of withdrawal. Some relapses accompanied arrhythmias, infection, pregnancy or uncontrolled blood pressure. The researchers suggested that lower treatment intensity, external triggers and disease progression could contribute. These findings support continued surveillance while leaving uncertainty about who can safely reduce treatment.

How should medication be reviewed when heart failure is in remission?

Ejection fraction measures the proportion of blood the left ventricle pumps out with each beat. The 2022 AHA/ACC/HFSA guideline recommends continuing guideline-directed treatment in people with heart failure and improved ejection fraction, including those without symptoms, to prevent recurrent dysfunction. A reassuring scan alone is therefore insufficient evidence that treatment has become unnecessary. [American College of Cardiology guideline summary](https://www.acc.org/latest-in-cardiology/articles/2022/04/01/01/42/feature-patient-centered-recommendations-focus-of-new-hf-guideline)

Modern treatment for reduced-ejection-fraction heart failure includes several complementary drug classes: an ARNI, ACE inhibitor or ARB; an evidence-based beta-blocker; a mineralocorticoid receptor antagonist; and an SGLT2 inhibitor. TRED-HF did not separately test withdrawal of today's complete regimen. Medication reviews should address each prescription's purpose and tolerability, with changes directed by the treating clinician. The clinical question is whether protection remains necessary despite improvement, rather than whether the patient still feels ill.